

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>New antipsychotic drugs for the treatment of... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-686/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-686" />
    
            <meta name="description" content="Read the original article in full on F1000Research: New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin" />
    
            <meta name="og:title" content="F1000Research Article: New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer&rsquo;s disease: focus on brexpiprazole and pimavanserin.">
            <meta name="og:description" content="Read the latest article version by Filippo Caraci, Mario Santagati, Giuseppe Caruso, Dario Cannav&ograve;, Gian Marco Leggio, Salvatore Salomone, Filippo Drago, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="25019">
            <meta name="article-id" content="22662">
            <meta name="dc.title" content="New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer&rsquo;s disease: focus on brexpiprazole and pimavanserin">
            <meta name="dc.description" content="Behavioral and psychological symptoms of dementia are symptoms of disturbed perception, mood, behavior, and thought content that occurred frequently. These symptoms, which include apathy, depression, anxiety, psychosis, agitation, and aggression, can serve as predictors of and early clinical diagnostic markers for Alzheimer&rsquo;s disease (AD) and are common precipitants of institutional care. Agitation and psychosis are associated with accelerated disease progression and increased tau phosphorylation in patients with AD. Current guidelines recommend the use of second-generation antipsychotics for the treatment of agitation and psychosis in AD, but only after first-line non-pharmacological interventions and for no longer than 12 weeks because long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs. In this report, we discuss some of the most relevant advances in the field of agitation and psychosis in AD and focus on the recent positive clinical evidence observed with two new antipsychotics drugs: brexpiprazole and pimavanserin. Brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, &alpha;1B/&alpha;2C) according to the neuroscience-based nomenclature. Two recent phase III clinical trials have shown that brexpiprazole 2 mg/day is effective for the treatment of agitation in patients with AD and has an improved tolerability and safety profile compared with currently available second-generation antipsychotics. Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson&rsquo;s disease. Recent phase II studies suggest that this drug is effective in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin for the treatment of psychosis in AD.">
            <meta name="dc.subject" content="Alzheimer&rsquo;s disease, agitation, psychosis,  second-generation antipsychotics, brexpiprazole, pimavanserin">
            <meta name="dc.creator" content="Caraci, Filippo">
            <meta name="dc.creator" content="Santagati, Mario">
            <meta name="dc.creator" content="Caruso, Giuseppe">
            <meta name="dc.creator" content="Cannav&ograve;, Dario">
            <meta name="dc.creator" content="Leggio, Gian Marco">
            <meta name="dc.creator" content="Salomone, Salvatore">
            <meta name="dc.creator" content="Drago, Filippo">
            <meta name="dc.date" content="2020/07/08">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22662.1">
            <meta name="dc.source" content="F1000Research 2020 9:686">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Alzheimer&rsquo;s disease">
            <meta name="prism.keyword" content="agitation">
            <meta name="prism.keyword" content="psychosis">
            <meta name="prism.keyword" content="second-generation antipsychotics">
            <meta name="prism.keyword" content="brexpiprazole">
            <meta name="prism.keyword" content="pimavanserin">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/07/08">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="686">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22662.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-686">
            <meta name="citation_title" content="New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer&rsquo;s disease: focus on brexpiprazole and pimavanserin">
            <meta name="citation_abstract" content="Behavioral and psychological symptoms of dementia are symptoms of disturbed perception, mood, behavior, and thought content that occurred frequently. These symptoms, which include apathy, depression, anxiety, psychosis, agitation, and aggression, can serve as predictors of and early clinical diagnostic markers for Alzheimer&rsquo;s disease (AD) and are common precipitants of institutional care. Agitation and psychosis are associated with accelerated disease progression and increased tau phosphorylation in patients with AD. Current guidelines recommend the use of second-generation antipsychotics for the treatment of agitation and psychosis in AD, but only after first-line non-pharmacological interventions and for no longer than 12 weeks because long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs. In this report, we discuss some of the most relevant advances in the field of agitation and psychosis in AD and focus on the recent positive clinical evidence observed with two new antipsychotics drugs: brexpiprazole and pimavanserin. Brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, &alpha;1B/&alpha;2C) according to the neuroscience-based nomenclature. Two recent phase III clinical trials have shown that brexpiprazole 2 mg/day is effective for the treatment of agitation in patients with AD and has an improved tolerability and safety profile compared with currently available second-generation antipsychotics. Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson&rsquo;s disease. Recent phase II studies suggest that this drug is effective in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin for the treatment of psychosis in AD.">
            <meta name="citation_description" content="Behavioral and psychological symptoms of dementia are symptoms of disturbed perception, mood, behavior, and thought content that occurred frequently. These symptoms, which include apathy, depression, anxiety, psychosis, agitation, and aggression, can serve as predictors of and early clinical diagnostic markers for Alzheimer&rsquo;s disease (AD) and are common precipitants of institutional care. Agitation and psychosis are associated with accelerated disease progression and increased tau phosphorylation in patients with AD. Current guidelines recommend the use of second-generation antipsychotics for the treatment of agitation and psychosis in AD, but only after first-line non-pharmacological interventions and for no longer than 12 weeks because long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs. In this report, we discuss some of the most relevant advances in the field of agitation and psychosis in AD and focus on the recent positive clinical evidence observed with two new antipsychotics drugs: brexpiprazole and pimavanserin. Brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, &alpha;1B/&alpha;2C) according to the neuroscience-based nomenclature. Two recent phase III clinical trials have shown that brexpiprazole 2 mg/day is effective for the treatment of agitation in patients with AD and has an improved tolerability and safety profile compared with currently available second-generation antipsychotics. Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson&rsquo;s disease. Recent phase II studies suggest that this drug is effective in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin for the treatment of psychosis in AD.">
            <meta name="citation_keywords" content="Alzheimer&rsquo;s disease, agitation, psychosis,  second-generation antipsychotics, brexpiprazole, pimavanserin">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Filippo Caraci">
            <meta name="citation_author_institution" content="Department of Drug Sciences, University of Catania, Viale Andrea Doria 6, 95125, Catania, Italy">
            <meta name="citation_author_institution" content="Oasi Research Institute - IRCCS, Via Conte Ruggero 73, 94018, Troina, Italy">
            <meta name="citation_author" content="Mario Santagati">
            <meta name="citation_author_institution" content="ASP3 Catania, Department of Mental Health, Alzheimer Psychogeriatric Center Corso Italia 234, 95127, Catania, Italy">
            <meta name="citation_author" content="Giuseppe Caruso">
            <meta name="citation_author_institution" content="Oasi Research Institute - IRCCS, Via Conte Ruggero 73, 94018, Troina, Italy">
            <meta name="citation_author" content="Dario Cannav&ograve;">
            <meta name="citation_author_institution" content="ASP3 Catania, Department of Mental Health, Alzheimer Psychogeriatric Center Corso Italia 234, 95127, Catania, Italy">
            <meta name="citation_author" content="Gian Marco Leggio">
            <meta name="citation_author_institution" content="Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123, Catania, Italy">
            <meta name="citation_author" content="Salvatore Salomone">
            <meta name="citation_author_institution" content="Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123, Catania, Italy">
            <meta name="citation_author" content="Filippo Drago">
            <meta name="citation_author_institution" content="Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123, Catania, Italy">
            <meta name="citation_publication_date" content="2020/07/08">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="686">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22662.1">
            <meta name="citation_firstpage" content="686">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-686/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-686.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=25019 /> <input type=hidden id=articleId name=articleId value=22662 /> <input type=hidden id=xmlUrl value="/articles/9-686/v1/xml"/> <input type=hidden id=xmlFileName value="-9-686-v1.xml"> <input type=hidden id=article_uuid value=0eb7289e-aacb-40eb-910c-acd2cc85c13c /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22662.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22662.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-686"
  },
  "headline": "New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on...",
  "datePublished": "2020-07-08T14:48:33",
  "dateModified": "2020-07-08T14:48:33",
  "author": [
    {
      "@type": "Person",
      "name": "Filippo Caraci"
    },    {
      "@type": "Person",
      "name": "Mario Santagati"
    },    {
      "@type": "Person",
      "name": "Giuseppe Caruso"
    },    {
      "@type": "Person",
      "name": "Dario Cannav&ograve;"
    },    {
      "@type": "Person",
      "name": "Gian Marco Leggio"
    },    {
      "@type": "Person",
      "name": "Salvatore Salomone"
    },    {
      "@type": "Person",
      "name": "Filippo Drago"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Behavioral and psychological symptoms of dementia are symptoms of disturbed perception, mood, behavior, and thought content that occurred frequently. These symptoms, which include apathy, depression, anxiety, psychosis, agitation, and aggression, can serve as predictors of and early clinical diagnostic markers for Alzheimer&rsquo;s disease (AD) and are common precipitants of institutional care. Agitation and psychosis are associated with accelerated disease progression and increased tau phosphorylation in patients with AD. Current guidelines recommend the use of second-generation antipsychotics for the treatment of agitation and psychosis in AD, but only after first-line non-pharmacological interventions and for no longer than 12 weeks because long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs. In this report, we discuss some of the most relevant advances in the field of agitation and psychosis in AD and focus on the recent positive clinical evidence observed with two new antipsychotics drugs: brexpiprazole and pimavanserin. Brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, &alpha;1B/&alpha;2C) according to the neuroscience-based nomenclature. Two recent phase III clinical trials have shown that brexpiprazole 2 mg/day is effective for the treatment of agitation in patients with AD and has an improved tolerability and safety profile compared with currently available second-generation antipsychotics. Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson&rsquo;s disease. Recent phase II studies suggest that this drug is effective in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin for the treatment of psychosis in AD."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-686/v1",
            "name": "New antipsychotic drugs for the treatment of agitation and psychosis..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> New antipsychotic drugs for the treatment of agitation and psychosis... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=25019 data-id=22662 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22662.1" data-recommended="" data-doi="10.12688/f1000research.22662.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-686/v1/pdf?article_uuid=0eb7289e-aacb-40eb-910c-acd2cc85c13c" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22662-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22662-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22662-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Caraci F, Santagati M, Caruso G <em>et al.</em> New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):686 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22662.1" target=_blank>https://doi.org/10.12688/f1000research.22662.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22662-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22662 id=track-article-signin-22662 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22662?target=/articles/9-686/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=25019 /> <input name=articleId type=hidden value=22662 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin</h1><span class=other-info> [version 1; peer review: 2 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:carafil@hotmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Caraci</span></a><a href="https://orcid.org/0000-0002-9867-6054" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9867-6054</div><sup>1,2</sup>,&nbsp;</span><span class="">Mario Santagati<sup>3</sup>,&nbsp;</span><span class="">Giuseppe Caruso<sup>2</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Dario Cannav&ograve;<sup>3</sup>,&nbsp;</span><span class="">Gian Marco Leggio<sup>4</sup>,&nbsp;</span><span class="">Salvatore Salomone<sup>4</sup>,&nbsp;</span><span class=""><a href="mailto:f.drago@unict.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Drago</span></a><sup>4</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:carafil@hotmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Caraci</span></a><a href="http://orcid.org/0000-0002-9867-6054" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9867-6054</div><sup>1,2</sup>,&nbsp;</span><span class="">Mario Santagati<sup>3</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Giuseppe Caruso<sup>2</sup>,&nbsp;</span><span class=article-page-hidden-authors>Dario Cannav&ograve;<sup>3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Gian Marco Leggio<sup>4</sup>,&nbsp;</span><span class="">Salvatore Salomone<sup>4</sup>,&nbsp;</span><span class=""><a href="mailto:f.drago@unict.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Drago</span></a><sup>4</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 08 Jul 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22662.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Drug Sciences, University of Catania, Viale Andrea Doria 6, 95125, Catania, Italy<br/> <sup>2</sup> Oasi Research Institute - IRCCS, Via Conte Ruggero 73, 94018, Troina, Italy<br/> <sup>3</sup> ASP3 Catania, Department of Mental Health, Alzheimer Psychogeriatric Center Corso Italia 234, 95127, Catania, Italy<br/> <sup>4</sup> Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123, Catania, Italy<br/> <p> <div class=margin-bottom> Filippo Caraci <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Mario Santagati <br/> <span>Roles: </span> Conceptualization, Resources, Writing – Original Draft Preparation </div> <div class=margin-bottom> Giuseppe Caruso <br/> <span>Roles: </span> Data Curation, Methodology, Writing – Original Draft Preparation </div> <div class=margin-bottom> Dario Cannav&ograve; <br/> <span>Roles: </span> Data Curation, Writing – Review & Editing </div> <div class=margin-bottom> Gian Marco Leggio <br/> <span>Roles: </span> Resources, Writing – Original Draft Preparation </div> <div class=margin-bottom> Salvatore Salomone <br/> <span>Roles: </span> Data Curation, Writing – Review & Editing </div> <div class=margin-bottom> Filippo Drago <br/> <span>Roles: </span> Supervision, Writing – Original Draft Preparation </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=71379-66691></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=71380-66692></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Behavioral and psychological symptoms of dementia are symptoms of disturbed perception, mood, behavior, and thought content that occurred frequently. These symptoms, which include apathy, depression, anxiety, psychosis, agitation, and aggression, can serve as predictors of and early clinical diagnostic markers for Alzheimer’s disease (AD) and are common precipitants of institutional care. Agitation and psychosis are associated with accelerated disease progression and increased tau phosphorylation in patients with AD. Current guidelines recommend the use of second-generation antipsychotics for the treatment of agitation and psychosis in AD, but only after first-line non-pharmacological interventions and for no longer than 12 weeks because long-term use of these drugs is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs. In this report, we discuss some of the most relevant advances in the field of agitation and psychosis in AD and focus on the recent positive clinical evidence observed with two new antipsychotics drugs: brexpiprazole and pimavanserin. Brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, α1B/α2C) according to the neuroscience-based nomenclature. Two recent phase III clinical trials have shown that brexpiprazole 2 mg/day is effective for the treatment of agitation in patients with AD and has an improved tolerability and safety profile compared with currently available second-generation antipsychotics. Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis occurring in Parkinson’s disease. Recent phase II studies suggest that this drug is effective in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin for the treatment of psychosis in AD. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Alzheimer’s disease, agitation, psychosis, second-generation antipsychotics, brexpiprazole, pimavanserin </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Filippo Caraci (<a href="mailto:carafil@hotmail.com">carafil@hotmail.com</a>) <br> Filippo Drago (<a href="mailto:f.drago@unict.it">f.drago@unict.it</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Filippo Caraci, Filippo Drago </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Caraci F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Caraci F, Santagati M, Caruso G <em>et al.</em> New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin [version 1; peer review: 2 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):686 (<a href="https://doi.org/10.12688/f1000research.22662.1" target=_blank>https://doi.org/10.12688/f1000research.22662.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 08 Jul 2020, <b>9</b>(Faculty Rev):686 (<a href="https://doi.org/10.12688/f1000research.22662.1" target=_blank>https://doi.org/10.12688/f1000research.22662.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 08 Jul 2020, <b>9</b>(Faculty Rev):686 (<a href="https://doi.org/10.12688/f1000research.22662.1" target=_blank>https://doi.org/10.12688/f1000research.22662.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d10647e245>Behavioral and psychological symptoms in Alzheimer’s disease</h2><p class="" id=d10647e248>Alzheimer’s disease (AD) is the most common form of dementia. Recent epidemiological data indicate that the number of people with AD worldwide will grow from the current 46.8 million to 131.5 million by 2050<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. AD is a neurodegenerative disorder characterized by memory deficit, cognitive decline, and neuropsychiatric symptoms, the so-called behavioral and psychological symptoms of dementia (BPSD)<sup><a href="#ref-3">3</a></sup>. According to the definition of the International Psychogeriatric Association, BPSD are “symptoms of disturbed perception, thought content, mood, and behavior frequently occurring in patients with dementia”<sup><a href="#ref-3">3</a></sup>. These symptoms include apathy, depression, anxiety, psychosis, agitation, aggression, sleep disturbances, wandering, and sexually inappropriate behaviors<sup><a href="#ref-3">3</a></sup>.</p><p class="" id=d10647e270>BPSD are common on inpatient psychogeriatric units (up to 90% of patients with diagnosed dementia) and are associated with a high economic burden<sup><a href="#ref-4">4</a></sup>. BPSD prevent patients with AD from living at home or in residential/nursing home settings<sup><a href="#ref-3">3</a></sup>. A strong neurobiological and clinical link has been demonstrated between cognitive dysfunction and neuropsychiatric symptoms in the pathophysiology of AD. BPSD are associated with accelerated disease progression<sup><a href="#ref-5">5</a></sup>. Recent studies show that they occur in an early phase of AD pathogenesis and are associated with greater amyloid deposition in the neurodegenerative process leading to AD<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. Amyloid dysmetabolism and the accumulation of amyloid plaques, consisting of aggregates of a 42-amino acid peptide called amyloid beta (Aβ<sub>1-42</sub>), are two primary events in the pathophysiology of AD<sup><a href="#ref-8">8</a>,<a href="#ref-9">9</a></sup>. It is generally believed that oligomeric species of Aβ<sub>1-42</sub> represent only the key initiator of a complex pathogenic cascade that includes microglia activation, hyperphosphorylation of tau protein, synaptic dysfunction, and finally neuronal death<sup><a href="#ref-10">10</a></sup>. According to this scenario, recent neuropathological studies suggest that BPSD are fundamental expressions of the underlying neurodegenerative brain disease in an early stage of AD and do not simply reflect the patient’s secondary response to his or her illness or just a behavioral product of diffuse brain disease<sup><a href="#ref-11">11</a></sup>. In particular, disruption of a cohesive noradrenergic locus coeruleus-thalamus linked system, owing to advanced neurodegeneration of locus coeruleus, has been proposed to lead to psychotic-like behavior in AD<sup><a href="#ref-11">11</a></sup>, in combination with an overactivation of dopamine D2 receptors in the mesolimbic pathway and hyperactive serotonin at 5-HT2A receptors in the cortex. Compared with patients with AD, those with psychosis of AD have shown significantly increased density of amyloid plaques and neurofibrillary tangles in the prosubiculum and middle frontal cortex and four/fivefold greater levels of abnormal tau protein in the entorhinal and temporal cortices<sup><a href="#ref-11">11</a></sup>. These neuropathological data can help explain epidemiological evidence where BPSD are more powerful predictors of incident mild cognitive impairment (MCI) than hippocampal atrophy<sup><a href="#ref-12">12</a></sup> and can serve as predictors of progression from MCI to dementia, as demonstrated in two very large cohort studies<sup><a href="#ref-5">5</a>,<a href="#ref-13">13</a></sup>. In particular, the Cache County Dementia Progression Study, a longitudinal study of dementia progression conducted in 335 patients with incident AD, demonstrated that psychosis and agitation/aggression were associated with more rapid progression to severe dementia<sup><a href="#ref-5">5</a></sup>. A large cohort longitudinal study was performed in 1821 subjects with MCI and collected clinical data from 29 AD centers. Interestingly, this study found that neuropsychiatric symptoms such as depression and agitation may be among the earliest symptoms of preclinical stages of AD and were associated with a significantly increased risk of incident dementia and AD<sup><a href="#ref-13">13</a></sup>.</p><p class="" id=d10647e342>Recently, it was suggested that mild behavioral impairment, a neurobehavioral syndrome characterized by clinically relevant neuropsychiatric symptoms, represented a prodromal stage of AD and would be considered a novel target for future AD clinical trials and secondary-prevention strategies in patients with preclinical AD<sup><a href="#ref-14">14</a></sup>. Therefore, a deep understanding of the pathophysiology of BPSD in AD represents an essential step for the design of disease-modifying drugs able to counteract the progression of AD.</p><p class="" id=d10647e349>In this scenario, transgenic animal models of AD are an important tool to investigate the pathology underlying BPSD in human AD patients showing the early occurrence of behavioral symptoms in AD<sup><a href="#ref-15">15</a></sup>. In particular, animal models that exhibit the widespread amyloid or tau pathology such as 5xFAD (or both), human APP-overexpressing transgenic mice, or 3xTg-AD exhibit increased aggression in the resident/intrusion task relative to wild-type controls<sup><a href="#ref-15">15</a></sup>. In the near future, these animal models might help to identify new pharmacological targets for the treatment of specific BPSD such as aggression and agitation.</p><p class="" id=d10647e361>Unfortunately, current drugs for AD (three cholinesterase inhibitors and memantine) are officially approved in the EU for the treatment of cognitive deficits in AD, but none of these drugs has shown significant disease-modifying activity and clinically relevant efficacy against BPSD. The sole medication approved for the treatment of BPSD in AD (Canada and Europe only) is risperidone, which is limited to short-term treatment of aggression<sup><a href="#ref-16">16</a></sup>. First-generation antipsychotics, such as haloperidol, and second-generation antipsychotics, such as olanzapine and quetiapine, are commonly used off-label in the management of psychosis and agitation in AD patients despite a modest effect size and considerable safety concerns<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>.</p><p class="" id=d10647e375>A major goal in the treatment of BPSD in patients with AD is to reduce agitation (that is, the inability to stay calm, motor and verbal hyperactivity, and hyper-responsiveness until loss of control and aggressiveness) without inducing sedation in elderly patients<sup><a href="#ref-19">19</a></sup>. Sedation should be considered an adverse effect to be avoided in elderly patients with a high frailty index since it is associated with an increased cognitive impairment and an increased risk of falls and mortality<sup><a href="#ref-20">20</a></sup>. Frailty represents a limiting factor in elderly patients in the treatment of BPSD and can increase the vulnerability side effects of antipsychotics. Frailty can be either physical or psychological or a combination of the two<sup><a href="#ref-21">21</a></sup>. Frailty is associated with impaired cognitive performance, and the presence of physical frailty increases BPSD burden in patients with AD<sup><a href="#ref-22">22</a></sup>. According to this scenario, non‐pharmacological approaches are usually the first option when addressing BPSD in frail patients with AD, but when these are unsuccessful and risk of self‐harm or harm to others persists, pharmacological treatment is needed<sup><a href="#ref-19">19</a></sup>.</p><p class="" id=d10647e398>Current guidelines recommend the use of antipsychotic drugs, but only after first-line non-pharmacological interventions and for no longer than 12 weeks<sup><a href="#ref-17">17</a>,<a href="#ref-23">23</a></sup> because the long-term use is associated with an increased risk of mortality and an increased frequency of cerebrovascular events in patients with dementia<sup><a href="#ref-18">18</a>,<a href="#ref-24">24</a></sup>. The long-term administration of antipsychotics is recommended only in patients with extremely severe initial manifestations of BPSD<sup><a href="#ref-3">3</a>,<a href="#ref-18">18</a></sup>.</p><p class="" id=d10647e422>Recent international consensus panels and algorithm-based approaches have suggested alternative pharmacological approaches when antipsychotics failed, such as the use of carbamazepine (neuroscience-based nomenclature [NbN]: glutamate: voltage-gated sodium and calcium channel blocker, step 3); citalopram (NbN: serotonin reuptake inhibitor, step 4), gabapentin (NbN: glutamate: voltage-gated calcium channel blocker, step 5), and prazosin (NbN: noradrenaline receptor antagonist, step 6), although they show limited effectiveness compared with second-generation antipsychotics<sup><a href="#ref-19">19</a></sup>. The algorithm also allows for the possibility of supplementing medication given in the main sequence with drugs. Interestingly, trazodone (NbN: serotonin receptor antagonist and receptor agonist) was selected as the drug of choice and can be used, for example, in combination with antipsychotics (it might help to reduce the dose of antipsychotics) or other drugs in the main algorithm sequence<sup><a href="#ref-19">19</a></sup>.</p><p class="" id=d10647e433>As discussed above, second-generation antipsychotics remain the mainstay for the treatment of agitation and aggression in patients with AD. A meta-analysis of 23 randomized controlled trials examined the clinical efficacy of second-generation antipsychotics in the treatment of BPSD in comparison with placebo and demonstrated that aripiprazole (overall BPSD symptoms) and risperidone (psychosis, agitation, and overall BPSD symptoms) performed better than placebo in reducing neuropsychiatric symptoms<sup><a href="#ref-18">18</a></sup>. A previous Agency for Healthcare Research and Quality (AHRQ) Comparative Effectiveness Review included olanzapine (agitation) among the most effective antipsychotics<sup><a href="#ref-25">25</a></sup>, whereas evidence from a meta-analysis shows that quetiapine, though commonly prescribed, has no effect on BPSD at the dosages commonly prescribed<sup><a href="#ref-26">26</a></sup>, showing an effectiveness for BPSD only at higher doses (100–200 mg/day), which may not be well tolerated<sup><a href="#ref-23">23</a></sup>. On the basis of this evidence, new antipsychotic drugs with improved efficacy and safety are needed as an alternative to current antipsychotic drugs for the treatment of agitation and psychosis in AD<sup><a href="#ref-17">17</a></sup>.</p><p class="" id=d10647e456>Much effort has been expended in the last five years to develop new drugs for the treatment of these BPSD in AD. In this commentary, we will briefly examine some of the most relevant advances in this field, focusing on the recent positive clinical evidence observed with two new antipsychotic drugs: brexpiprazole and pimavanserin.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10647e462>Brexipiprazole for the treatment of agitation in Alzheimer’s disease</h2><p class="" id=d10647e465>Agitation is one of the most distressing neuropsychiatric symptoms in patients with dementia and it affects at least 50% of patients with AD<sup><a href="#ref-27">27</a></sup>. The deficit of the cholinergic system appears more severe in AD patients displaying agitation or aggression<sup><a href="#ref-11">11</a>,<a href="#ref-28">28</a></sup>. AD is also associated with widespread deficits of the serotoninergic system in the hippocampus and in the frontal lobe. The impairment of serotoninergic system can partially contribute to explain the onset of agitation and irritability in AD patients<sup><a href="#ref-11">11</a>,<a href="#ref-29">29</a></sup>; dopaminergic alterations have also been reported, and an increased dopaminergic cerebellar turnover is linked to physically agitated behavior<sup><a href="#ref-30">30</a></sup>.</p><p class="" id=d10647e490>According to the definition proposed by the Agitation Definition Workgroup of the International Psychogeriatric Association, agitation in patients with cognitive disorders or dementia is consistent with emotional distress, including excessive motor activity, verbal aggression, or physical aggression and causes excess disability with regard to interpersonal relationships, social functioning, or activities of daily living, not attributable to another disorder (psychiatric, medical, or substance-related)<sup><a href="#ref-31">31</a></sup>. The Cohen-Mansfield Agitation Inventory (CMAI) is a 29-item, clinician-rated, 7-point scale and is a well-validated psychometric tool that can be used to assess both aggressive and non-aggressive behavior in clinical trials<sup><a href="#ref-32">32</a></sup>. Currently, no drugs are approved by the European Medicine Agency (EMA) or the US Food and Drug Administration (FDA) with a specific indication for agitation in AD. Brexpiprazole is a novel third-generation antipsychotic that acts as a dopamine D2 partial agonist, a partial agonist at serotonin 5-HT1A receptor, an antagonist at serotonin 5-HT2A/5-HT2B, and noradrenaline α1B/α2C receptors<sup><a href="#ref-33">33</a></sup>. Brexpiprazole has recently been approved by the FDA for the treatment of schizophrenia<sup><a href="#ref-34">34</a></sup> and as adjunctive treatment to antidepressants for the treatment of major depressive disorder<sup><a href="#ref-35">35</a></sup>. Interestingly, in 2019, two distinct phase III clinical trials, with a total of nearly 700 adult participants with AD, reported that brexpiprazole 2 mg/day had the potential to be an efficacious, safe, and well-tolerated treatment for agitation in patients with AD<sup><a href="#ref-36">36</a></sup>.</p><p class="" id=d10647e518>According to the new NbN, novel psychotropic drugs, including antipsychotics, can be classified on the basis of their pharmacology and mechanism of action in order to provide physicians with clearer alternatives than the Anatomical Therapeutic Chemical system when deciding the proper therapeutic strategy<sup><a href="#ref-37">37</a></sup>. The bases for NbN are first and foremost the pharmacological domains (that is, dopamine, serotonin, and so on) and modes of action (receptor antagonist, receptor partial agonist, reuptake inhibitor, and so on) (<a target=xrefwindow href="https://nbn2r.com/" id=d10647e524>https://nbn2r.com/</a>). According to the NbN, brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, α1B/α2C). Interestingly, this drug also acts as an antagonist at histamine H1 receptor with a threefold higher affinity than aripiprazole<sup><a href="#ref-38">38</a></sup>. This pharmacodynamic property can probably help explain its clinically relevant efficacy against agitation in patients with AD.</p><p class="" id=d10647e532>The new evidence on brexpiprazole stems from two 12-week, randomized, double-blind, placebo-controlled, parallel-arm studies (NCT01862640 andNCT01922258) well conducted in AD patients with clinically relevant symptoms of agitation or aggression confirmed by a score of at least 4 on the Neuropsychiatric Inventory - Nursing Home version (NPI-NH) Agitation/Aggression domain<sup><a href="#ref-36">36</a></sup>. Study 1 investigated two fixed doses of brexpiprazole (2 mg/day and 1mg/day), whereas study 2 investigated flexibly dosed brexpiprazole (0.5−2 mg/day). The primary efficacy endpoint was the change from baseline to week 12 in CMAI total score. In the first study, brexpiprazole 2 mg/day demonstrated statistically significantly greater improvement in CMAI total scores from baseline to week 12 than placebo; in the second study, <i>post hoc</i> analyses showed that only patients who were titrated to brexpiprazole 2 mg/day at week 4 demonstrated superiority over matched placebo patients<sup><a href="#ref-36">36</a></sup>. Interestingly, brexpiprazole 0.5−2 mg was safe and well tolerated in patients with AD with mild or moderate treatment-emergent adverse events (headache, dizziness, and somnolence). These data suggest that the slow brexpiprazole titration schedule (4 weeks) adopted in these two studies may show both higher clinical efficacy against agitation and improved tolerability and safety profile compared with currently available second-generation antipsychotics drugs. Notably, these two trials included only patients with AD, excluding individuals with a history of stroke or vascular dementia, in contrast with past clinical trials with risperidone and olanzapine, conducted in highly heterogeneous groups of patients with dementia. Three different phase III clinical trials are underway to evaluate the long-term safety and clinical efficacy of brexpiprazole in AD patients with agitation (NCT03724942, NCT03594123, and NCT03545584). These studies will be relevant for fast approval from the FDA and EMA of brexpiprazole as a new antipsychotic drug for the treatment of agitation in AD.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10647e549>Pimavanserin for the treatment of psychosis in Alzheimer’s disease</h2><p class="" id=d10647e552>Psychosis, defined by the emergence of delusions and hallucinations, is somewhat distinct from other BPSD and occurs in 30% of patients with AD<sup><a href="#ref-17">17</a></sup>. As discussed above, the neurobiology of psychosis in AD involves different neurotransmitter systems (dopamine, serotonine, acetylcholine, and noradrenaline) and is strictly linked to the severity of cognitive decline and to increased levels of tau phosphorylation in the frontal cortex of patients with AD<sup><a href="#ref-39">39</a>,<a href="#ref-40">40</a></sup>. Therefore, it is expected that future anti-tau disease-modifying drugs might exert a relevant clinical efficacy against both cognitive and neuropsychiatric symptoms in patients with AD<sup><a href="#ref-17">17</a></sup>.</p><p class="" id=d10647e570>Pimavanserin is a new 5-HT2A receptor acting drug that has been given market authorization for Parkinson’s disease psychosis (PDP) with recommended doses of 34 to 40 mg once daily<sup><a href="#ref-41">41</a></sup>. According to the NbN, pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C). The FDA has termed it an inverse agonist but this conclusion is based on <i>in vitro</i> data<sup><a href="#ref-42">42</a></sup>, and recent studies suggest that pimavanserin functions primarily as an antagonist at 5-HT2A receptors<sup><a href="#ref-43">43</a></sup>. Selectivity for 5-HT2 receptors and sparing the dopamine post-synaptic receptors differentiate pimavanserin from other antipsychotic drugs currently used in PDP. Pimavanserin binds with very high affinity (Ki 0.087nM) to 5-HT2A and fivefold lower affinity (Ki 0.44nM) to 5-HT2C and shows negligible binding at 5-HT2B and dopaminergic D3 receptors<sup><a href="#ref-43">43</a></sup>. Recently, pimavanserin received a 100% agreement from an international consensus panel when considering emerging and experimental pharmacological treatments for psychosis<sup><a href="#ref-44">44</a></sup>. This preliminary positive evaluation stems not only from the evidence of efficacy and tolerability of this drug in PDP patients with cognitive impairment (NCT00477672, NCT00658567, and NCT01174004)<sup><a href="#ref-41">41</a>,<a href="#ref-45">45</a></sup> but also from the relevant results observed in a phase II clinical study conducted in 181 AD patients with psychosis<sup><a href="#ref-46">46</a></sup>. The phase 3, double-blind, randomized, placebo-controlled study clearly demonstrated the efficacy of pimavanserin (34 mg once daily for 6 weeks) versus placebo in the treatment of hallucinations and delusions associated with PDP with a robust clinical effect (effect size: 0.50) assessed by the Parkinson’s disease–adapted scale for the assessment of positive symptoms (SAPS-PD)<sup><a href="#ref-45">45</a></sup>. Interestingly, a <i>post hoc</i> subgroup analysis conducted from this phase 3 study showed that pimavanserin exerted a more robust clinical effect (effect size: 0.99) in PDP patients with cognitive impairment<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d10647e619>The phase II clinical study conducted in patients with AD was a 12-week, randomized, double-blind, placebo-controlled, single-center study to assess the safety and efficacy of pimavanserin 34 mg once daily in 181 nursing home residents who had AD with psychosis<sup><a href="#ref-46">46</a></sup>. The primary endpoint was mean change from baseline at week 6 on the Neuropsychiatric Inventory-Nursing Home Version psychosis score (NPI-NH-PS), and AD patients with a score of at least 4 on either the hallucinations or delusions component or a combined hallucinations and delusions score of at least 6 on the NPI-NH-PS were recruited<sup><a href="#ref-46">46</a></sup>. At week 6 (but not at week 12), pimavanserin demonstrated a significant treatment effect versus placebo, including a treatment difference of −1.84 and a Cohen’s <i>d</i> effect size of 0.32, without inducing adverse effects on motor function or cognition. Interestingly, a recent subgroup analysis in patients with more severe psychosis at baseline (NPI-NH-PS ≥12) shows larger treatment effects (delta of−4.43 and Cohen’s <i>d</i> effect size of 0.73) with an at least 30% improvement of NPI-NH-PS in 88.9% of pimavanserin-treated patients versus 43.3% of placebo-treated patients<sup><a href="#ref-47">47</a></sup>. These results are particularly relevant when considering the low effect size (0.2) typically reported with second-generation antipsychotics<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup> and higher risk of mortality compared with placebo observed with these drugs<sup><a href="#ref-50">50</a></sup>. Furthermore, the tolerability profile of pimavanserin seems to be favorable with a rate of adverse events (urinary tract infection, fall, and agitation) similar between treatment groups<sup><a href="#ref-47">47</a></sup>, although the safety of the drug is being re-evaluated from May 2018 following reports of serious adverse events in patients with PDP<sup><a href="#ref-51">51</a></sup>. Pimavanserin can induce electrocardiographic QT-interval prolongation and is not recommended for patients with preexisting QT prolongation or a history of arrhythmias. Other pimavanserin-induced side effects include gait instability, falls, confusion, edema, and constipation. Further long-term studies are needed to better understand the safety profile of pimavanserin in patients with AD. In particular, a phase III, double-blind, placebo-controlled, relapse prevention study of pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis (DRP) (NCT03325556) is evaluating the efficacy and safety of pimavanserin in 360 individuals with DRP (<a href="#T1">Table 1</a>). The design of this study is interesting because it comprises a first period of 12 weeks of open-label treatment with a flexible dose of pimavanserin followed by blinded randomized withdrawal of treatment or continued pimavanserin therapy (20 or 34 mg) for 26 weeks<sup><a href="#ref-41">41</a></sup>. The study will be essential to validate the clinical efficacy of pimavanserin in the treatment of psychosis in different types of dementia, including not only AD but also vascular dementia, dementia with Lewy bodies, and frontotemporal dementia. Most importantly, this study will better define the long-term safety profile (38 weeks) in patients with DRP. The study was completed at the end of 2019 and results are awaited (<a target=xrefwindow href="https://clinicaltrials.gov" id=d10647e667>https://clinicaltrials.gov</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Current status of clinical development of brexpiprazole and pimavanserin for the treatment of agitation and psychosis in Alzheimer’s disease.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d10647e682 class=n-a></a><thead><a name=d10647e684 class=n-a></a><tr><a name=d10647e686 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d10647e688 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10647e691 class=n-a></a>Indication/Field</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10647e694 class=n-a></a>Phase of<br class=br>study of<br class=br>action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10647e701 class=n-a></a>Duration</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10647e704 class=n-a></a>Sample<br class=br>size</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10647e710 class=n-a></a>Dosing</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10647e713 class=n-a></a>Main result or status or both</th></tr></thead><tbody><a name=d10647e718 class=n-a></a><tr><a name=d10647e720 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e722 class=n-a></a>Brexpiprazole</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e725 class=n-a></a>Agitation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e728 class=n-a></a>III<br class=br><br class=br>Clinical trial:<br class=br>NCT01862640</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e736 class=n-a></a>12 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e739 class=n-a></a>433<br class=br>AD<br class=br>subjects</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e747 class=n-a></a>2mg/day<br class=br>Fixed dose</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e752 class=n-a></a>Brexpiprazole demonstrated<br class=br>superior efficacy versus<br class=br>placebo as assessed by CMAI.<br class=br><br class=br>Safe and well-tolerated</td></tr><tr><a name=d10647e763 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e765 class=n-a></a>Brexpiprazole</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e768 class=n-a></a>Agitation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e771 class=n-a></a>III<br class=br><br class=br>Clinical trial:<br class=br>NCT01922258</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e779 class=n-a></a>12 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e782 class=n-a></a>270<br class=br>AD<br class=br>subjects</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e790 class=n-a></a>Flexible dose<br class=br>in the range of<br class=br>0.5–2 mg/day</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e797 class=n-a></a>Patients who were titrated to<br class=br>brexpiprazole<br class=br><br class=br>2 mg/day at week 4<br class=br>demonstrated superiority<br class=br>versus matched placebo as<br class=br>assessed by CMAI.</td></tr><tr><a name=d10647e812 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e814 class=n-a></a>Brexpiprazole</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e817 class=n-a></a>Agitation</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e820 class=n-a></a>III<br class=br><br class=br>Clinical trials:<br class=br>NCT03724942,<br class=br><br class=br>NCT03594123,<br class=br><br class=br>NCT03620981</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e834 class=n-a></a><br class=br><br class=br>14 weeks<br class=br><br class=br>12 weeks<br class=br><br class=br>10 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e845 class=n-a></a><br class=br><br class=br>157 AD<br class=br><br class=br>250 AD<br class=br><br class=br>407 AD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e857 class=n-a></a><br class=br><br class=br>1–2 mg<br class=br><br class=br>2–3 mg<br class=br><br class=br>1–2 mg</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e868 class=n-a></a>Ongoing<br class=br><br class=br>To evaluate the long-term<br class=br>safety and clinical efficacy of<br class=br>brexpiprazole</td></tr><tr><a name=d10647e879 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e881 class=n-a></a>Pimavanserin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e884 class=n-a></a>Psychosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e887 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e890 class=n-a></a>12 weeks</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e893 class=n-a></a>181 AD</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e897 class=n-a></a>34 mg once daily</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e900 class=n-a></a>Large treatment effects in<br class=br>AD patients with more severe<br class=br>psychosis at baseline (NPI-NH-<br class=br>PS ≥12)</td></tr><tr><a name=d10647e910 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e912 class=n-a></a>Pimavanserin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e915 class=n-a></a>Psychosis</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e918 class=n-a></a>III<br class=br><br class=br>Clinical trial:<br class=br>NCT03325556</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e926 class=n-a></a>38 weeks<br class=br><br class=br>12 weeks<br class=br><br class=br>Open-<br class=br>label +<br class=br><br class=br>26 weeks<br class=br><br class=br>Double-<br class=br>blind<br class=br>period</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e948 class=n-a></a>360<br class=br>patients<br class=br>with DRP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e956 class=n-a></a>20 mg or 34 mg<br class=br>once daily based<br class=br>on their open-<br class=br>label phase</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10647e965 class=n-a></a>Ongoing<br class=br><br class=br>A long-term relapse prevention<br class=br>study of pimavanserin for the<br class=br>treatment of hallucinations and<br class=br>delusions associated with DRP</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=FN1 class=n-a></a><p id=d10647e984> AD, Alzheimer’s disease; CMAI, Cohen-Mansfield Agitation Inventory; DRP, dementia-related psychosis; NPI-NH-PS, Neuropsychiatric Inventory-Nursing Home Version psychosis score</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10647e993>Conclusions</h2><p class="" id=d10647e996>Considerable effort has been expended in the last five years to develop new antipsychotic drugs for the treatment of agitation and psychosis in AD, two BPSD that are strongly linked to disease progression and severity of cognitive decline in patients with AD. Current long-term use of second-generation antipsychotics is associated with an increased risk of mortality and an increased frequency of cerebrovascular events. Therefore, new antipsychotic drugs with improved efficacy and safety are needed in this area.</p><p class="" id=d10647e999>As indicated in this report, brexpiprazole and pimavanserin are two new antipsychotics drugs that recently showed positive clinical evidence of efficacy for the treatment of agitation and psychosis in AD. Brexpiprazole is a receptor partial agonist (D2, D3, 5-HT1A), receptor antagonist (5-HT2A/B, norepinephrine α1B/α2C) that exerts relevant clinical efficacy for the treatment of agitation in AD patients with an improved tolerability and safety profile compared with currently available second-generation antipsychotics drugs. Pimavanserin is a receptor antagonist (5-HT2A, 5-HT2C) that has been given market authorization for psychosis in PDP. Recent phase II studies suggest the efficacy of this drug in AD patients with more severe psychosis, although further long-term studies are needed to better define the efficacy and long-term safety profile of pimavanserin (in particular, the risk of QT-interval prolongation) in the treatment of psychosis in AD.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10647e1005>Abbreviations</h2><p class="" id=d10647e1008>5-HT, serotonin; Aβ, amyloid beta; AD, Alzheimer’s disease; BPSD, behavioral and psychological symptoms of dementia; CMAI, Cohen-Mansfield Agitation Inventory; DRP, dementia-related psychosis; EMA, European Medicine Agency; FDA, US Food and Drug Administration; MCI, mild cognitive impairment; NbN, neuroscience-based nomenclature; NPI-NH-PS, Neuropsychiatric Inventory-Nursing Home Version psychosis score; PDP, Parkinson’s disease psychosis</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d10647e1015 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d10978>References</h2><div class="section ref-list"><a name=d10647e1015 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d10647e1022 class=n-a></a>Prince M, Guerchet M, Prina M: Policy Brief for Heads of Government: The Global Impact of Dementia 2013–2050. London: Alzheimer's Disease International (ADI); 2013; [cited 2013 Dec 20]. <a target=xrefwindow id=d10647e1024 href="https://www.alz.co.uk/research/GlobalImpactDementia2013.pdf">Reference Source</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d10647e1033 class=n-a></a>Prince M, Wimo A, Guerchet M, <i> et al.</i>: Alzheimer’s Disease International: World Alzheimer Report 2015: The Global Impact of Dementia: an Analysis of Prevalence, Incidence, Cost and Trends. 2015. Alzheimer’s Disease International: London. 2019. <a target=xrefwindow id=d10647e1038 href="https://www.alz.co.uk/research/WorldAlzheimerReport2015-sheet.pdf">Reference Source</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736118219"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1047 class=n-a></a>Bessey LJ, Walaszek A: Management of Behavioral and Psychological Symptoms of Dementia. <i>Curr Psychiatry Rep.</i> 2019; <b>21</b>(8): 66. <a target=xrefwindow id=d10647e1055 href="http://www.ncbi.nlm.nih.gov/pubmed/31264056">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1058 href="https://doi.org/10.1007/s11920-019-1049-5">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736118219">Faculty Opinions Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d10647e1071 class=n-a></a>Beeri MS, Werner P, Davidson M, <i> et al.</i>: The cost of behavioral and psychological symptoms of dementia (BPSD) in community dwelling Alzheimer's disease patients. <i>Int J Geriatr Psychiatry.</i> 2002; <b>17</b>(5): 403–8. <a target=xrefwindow id=d10647e1082 href="http://www.ncbi.nlm.nih.gov/pubmed/11994927">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1085 href="https://doi.org/10.1002/gps.490">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d10647e1094 class=n-a></a>Peters ME, Schwartz S, Han D, <i> et al.</i>: Neuropsychiatric symptoms as predictors of progression to severe Alzheimer's dementia and death: The Cache County Dementia Progression Study. <i>Am J Psychiatry.</i> 2015; <b>172</b>(5): 460–5. <a target=xrefwindow id=d10647e1105 href="http://www.ncbi.nlm.nih.gov/pubmed/25585033">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1108 href="https://doi.org/10.1176/appi.ajp.2014.14040480">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1112 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4416978">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726473820"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1122 class=n-a></a>Lanctôt KL, Agüera-Ortiz L, Brodaty H, <i> et al.</i>: Apathy associated with neurocognitive disorders: Recent progress and future directions. <i>Alzheimers Dement.</i> 2017; <b>13</b>(1): 84–100. <a target=xrefwindow id=d10647e1133 href="http://www.ncbi.nlm.nih.gov/pubmed/27362291">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1136 href="https://doi.org/10.1016/j.jalz.2016.05.008">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726473820">Faculty Opinions Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725861261"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1149 class=n-a></a>Bensamoun D, Guignard R, Furst AJ, <i> et al.</i>: Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People. <i>J Alzheimers Dis.</i> 2016; <b>49</b>(2): 387–98. <a target=xrefwindow id=d10647e1160 href="http://www.ncbi.nlm.nih.gov/pubmed/26484900">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1163 href="https://doi.org/10.3233/JAD-150181">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725861261">Faculty Opinions Recommendation</a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d10647e1176 class=n-a></a>Caruso G, Spampinato SF, Cardaci V, <i> et al.</i>: β-amyloid and Oxidative Stress: Perspectives in Drug Development. <i>Curr Pharm Des.</i> 2019; <b>25</b>(45): 4771–81. <a target=xrefwindow id=d10647e1187 href="http://www.ncbi.nlm.nih.gov/pubmed/31814548">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1190 href="https://doi.org/10.2174/1381612825666191209115431">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d10647e1199 class=n-a></a>Musiek ES, Holtzman DM: Three dimensions of the amyloid hypothesis: Time, space and 'wingmen'. <i>Nat Neurosci.</i> 2015; <b>18</b>(6): 800–6. <a target=xrefwindow id=d10647e1207 href="http://www.ncbi.nlm.nih.gov/pubmed/26007213">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1210 href="https://doi.org/10.1038/nn.4018">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1213 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4445458">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735593508"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1222 class=n-a></a>Edwards FA: A Unifying Hypothesis for Alzheimer’s Disease: From Plaques to Neurodegeneration. <i>Trends Neurosci.</i> 2019; <b>42</b>(5): 310–22. <a target=xrefwindow id=d10647e1230 href="http://www.ncbi.nlm.nih.gov/pubmed/31006494">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1233 href="https://doi.org/10.1016/j.tins.2019.03.003">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735593508">Faculty Opinions Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/726328638"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1246 class=n-a></a>Van Dam D, Vermeiren Y, Dekker AD, <i> et al.</i>: Neuropsychiatric Disturbances in Alzheimer's Disease: What Have We Learned from Neuropathological Studies? <i>Curr Alzheimer Res.</i> 2016; <b>13</b>(10): 1145–64. <a target=xrefwindow id=d10647e1257 href="http://www.ncbi.nlm.nih.gov/pubmed/27137218">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1260 href="https://doi.org/10.2174/1567205013666160502123607">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1264 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5070416">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/726328638">Faculty Opinions Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d10647e1278 class=n-a></a>Geda YE, Roberts RO, Mielke MM, <i> et al.</i>: Baseline neuropsychiatric symptoms and the risk of incident mild cognitive impairment: A population-based study. <i>Am J Psychiatry.</i> 2014; <b>171</b>(5): 572–81. <a target=xrefwindow id=d10647e1289 href="http://www.ncbi.nlm.nih.gov/pubmed/24700290">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1292 href="https://doi.org/10.1176/appi.ajp.2014.13060821">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1296 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4057095">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/720632832"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1305 class=n-a></a>Rosenberg PB, Mielke MM, Appleby BS, <i> et al.</i>: The Association of Neuropsychiatric Symptoms in MCI with Incident Dementia and Alzheimer Disease. <i>Am J Geriatr Psychiatry.</i> 2013; <b>21</b>(7): 685–95. <a target=xrefwindow id=d10647e1316 href="http://www.ncbi.nlm.nih.gov/pubmed/23567400">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1319 href="https://doi.org/10.1016/j.jagp.2013.01.006">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1323 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3428504">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/720632832">Faculty Opinions Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737728409"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1336 class=n-a></a>Creese B, Griffiths A, Brooker H, <i> et al.</i>: Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>Int Psychogeriatr.</i> 2020; <b>32</b>(6): 1–13. <a target=xrefwindow id=d10647e1347 href="http://www.ncbi.nlm.nih.gov/pubmed/31526407">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1350 href="https://doi.org/10.1017/S1041610219001200">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737728409">Faculty Opinions Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737403340"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1363 class=n-a></a>Kosel F, Pelley JMS, Franklin TB: Behavioural and psychological symptoms of dementia in mouse models of Alzheimer’s disease-related pathology. <i>Neurosci Biobehav Rev.</i> 2020; <b>112</b>: 634–47. <a target=xrefwindow id=d10647e1371 href="http://www.ncbi.nlm.nih.gov/pubmed/32070692">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1374 href="https://doi.org/10.1016/j.neubiorev.2020.02.012">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737403340">Faculty Opinions Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d10647e1387 class=n-a></a>Corbett A, Smith J, Creese B, <i> et al.</i>: Treatment of behavioral and psychological symptoms of Alzheimer's disease. <i>Curr Treat Options Neurol.</i> 2012; <b>14</b>(2): 113–25. <a target=xrefwindow id=d10647e1398 href="http://www.ncbi.nlm.nih.gov/pubmed/22328204">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1401 href="https://doi.org/10.1007/s11940-012-0166-9">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733266883"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1410 class=n-a></a>Creese B, Da Silva MV, Johar I, <i> et al.</i>: The modern role of antipsychotics for the treatment of agitation and psychosis in Alzheimer's disease. <i>Expert Rev Neurother.</i> 2018; <b>18</b>(6): 461–7. <a target=xrefwindow id=d10647e1421 href="http://www.ncbi.nlm.nih.gov/pubmed/29764230">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1424 href="https://doi.org/10.1080/14737175.2018.1476140">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733266883">Faculty Opinions Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733303213"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1438 class=n-a></a>Masopust J, Protopopová D, Vališ M, <i> et al.</i>: Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: A review. <i>Neuropsychiatr Dis Treat.</i> 2018; <b>14</b>: 1211–20. <a target=xrefwindow id=d10647e1449 href="http://www.ncbi.nlm.nih.gov/pubmed/29785112">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1452 href="https://doi.org/10.2147/NDT.S163842">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1456 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5953267">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733303213">Faculty Opinions Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732500679"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1469 class=n-a></a>Davies SJc, Burhan AM, Kim D, <i> et al.</i>: Sequential drug treatment algorithm for agitation and aggression in Alzheimer's and mixed dementia. <i>J Psychopharmacol.</i> 2018; <b>32</b>(5): 509–23. <a target=xrefwindow id=d10647e1480 href="http://www.ncbi.nlm.nih.gov/pubmed/29338602">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1483 href="https://doi.org/10.1177/0269881117744996">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1487 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5944080">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732500679">Faculty Opinions Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d10647e1500 class=n-a></a>Moretti R, Torre P, Antonello RM, <i> et al.</i>: Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer's disease: Risks or benefits. <i>Expert Rev Neurother.</i> 2006; <b>6</b>(5): 705–10. <a target=xrefwindow id=d10647e1511 href="http://www.ncbi.nlm.nih.gov/pubmed/16734518">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1514 href="https://doi.org/10.1586/14737175.6.5.705">Publisher Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d10647e1523 class=n-a></a>Robertson DA, Savva GM, Kenny RA: Frailty and cognitive impairment--a review of the evidence and causal mechanisms. <i>Ageing Res Rev.</i> 2013; <b>12</b>(4): 840–51. <a target=xrefwindow id=d10647e1531 href="http://www.ncbi.nlm.nih.gov/pubmed/23831959">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1534 href="https://doi.org/10.1016/j.arr.2013.06.004">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734502820"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1543 class=n-a></a>Sugimoto T, Ono R, Kimura A, <i> et al.</i>: Physical Frailty Correlates With Behavioral and Psychological Symptoms of Dementia and Caregiver Burden in Alzheimer's Disease. <i>J Clin Psychiatry.</i> 2018; <b>79</b>(6): 17m11991. <a target=xrefwindow id=d10647e1554 href="http://www.ncbi.nlm.nih.gov/pubmed/30474939">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1557 href="https://doi.org/10.4088/JCP.17m11991">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734502820">Faculty Opinions Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d10647e1570 class=n-a></a>Reus VI, Fochtmann LJ, Eyler AE, <i> et al.</i>: The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. <i>Am J Psychiatry.</i> 2016; <b>173</b>(5): 543–6. <a target=xrefwindow id=d10647e1581 href="http://www.ncbi.nlm.nih.gov/pubmed/27133416">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1584 href="https://doi.org/10.1176/appi.ajp.2015.173501">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d10647e1594 class=n-a></a>Gill SS, Mamdani M, Naglie G, <i> et al.</i>: A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. <i>Arch Intern Med.</i> 2005; <b>165</b>(7): 808–13. <a target=xrefwindow id=d10647e1605 href="http://www.ncbi.nlm.nih.gov/pubmed/15824303">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1608 href="https://doi.org/10.1001/archinte.165.7.808">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d10647e1617 class=n-a></a>Maglione M, Maher AR, Hu J, <i> et al.</i>: AHRQ Comparative Effectiveness Reviews: Off-Label Use of Atypical Antipsychotics: An Update. Rockville (MD): Agency for Healthcare Research and Quality (US); 2011. <a target=xrefwindow id=d10647e1622 href="https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/atypical-antipsychotics-off-label-update_surveillance.pdf">Reference Source</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d10647e1631 class=n-a></a>Schneider LS, Dagerman K, Insel PS: Efficacy and Adverse Effects of Atypical Antipsychotics for Dementia: Meta-analysis of Randomized, Placebo-Controlled Trials. <i>Am J Geriatr Psychiatry.</i> 2006; <b>14</b>(3): 191–210. <a target=xrefwindow id=d10647e1639 href="http://www.ncbi.nlm.nih.gov/pubmed/16505124">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1642 href="https://doi.org/10.1097/01.JGP.0000200589.01396.6d">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727413134"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1651 class=n-a></a>Porsteinsson AP, Antonsdottir IM: An update on the advancements in the treatment of agitation in Alzheimer's disease. <i>Expert Opin Pharmacother.</i> 2017; <b>18</b>(6): 611–20. <a target=xrefwindow id=d10647e1659 href="http://www.ncbi.nlm.nih.gov/pubmed/28300462">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1662 href="https://doi.org/10.1080/14656566.2017.1307340">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727413134">Faculty Opinions Recommendation</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d10647e1675 class=n-a></a>Minger SL, Esiri MM, McDonald B, <i> et al.</i>: Cholinergic deficits contribute to behavioral disturbance in patients with dementia. <i>Neurology.</i> 2000; <b>55</b>(10): 1460–7. <a target=xrefwindow id=d10647e1686 href="http://www.ncbi.nlm.nih.gov/pubmed/11094098">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1689 href="https://doi.org/10.1212/WNL.55.10.1460">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d10647e1698 class=n-a></a>Siddique H, Hynan LS, Weiner MF: Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. <i>J Clin Psychiatry.</i> 2009; <b>70</b>(6): 915–8. <a target=xrefwindow id=d10647e1706 href="http://www.ncbi.nlm.nih.gov/pubmed/19422762">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1709 href="https://doi.org/10.4088/JCP.08m04828">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1712 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3236068">Free Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d10647e1722 class=n-a></a>Vermeiren Y, van Dam D, Aerts T, <i> et al.</i>: Brain Region-Specific Monoaminergic Correlates of Neuropsychiatric Symptoms in Alzheimer's Disease. <i>J Alzheimers Dis.</i> 2014; <b>41</b>(3): 819–33. <a target=xrefwindow id=d10647e1733 href="http://www.ncbi.nlm.nih.gov/pubmed/24685637">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1736 href="https://doi.org/10.3233/JAD-140309">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d10647e1745 class=n-a></a>Cummings J, Mintzer J, Brodaty H, <i> et al.</i>: Agitation in cognitive disorders: International Psychogeriatric Association provisional consensus clinical and research definition. <i>Int Psychogeriatr.</i> 2015; <b>27</b>(1): 7–17. <a target=xrefwindow id=d10647e1756 href="http://www.ncbi.nlm.nih.gov/pubmed/25311499">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1759 href="https://doi.org/10.1017/S1041610214001963">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1763 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4301197">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d10647e1772 class=n-a></a>Cohen-Mansfield J, Marx MS, Rosenthal AS: A Description of Agitation in a Nursing Home. <i>J Gerontol.</i> 1989; <b>44</b>(3): M77–M84. <a target=xrefwindow id=d10647e1780 href="http://www.ncbi.nlm.nih.gov/pubmed/2715584">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1783 href="https://doi.org/10.1093/geronj/44.3.M77">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d10647e1792 class=n-a></a>Maeda K, Sugino H, Akazawa H, <i> et al.</i>: Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. <i>J Pharmacol Exp Ther.</i> 2014; <b>350</b>(3): 589–604. <a target=xrefwindow id=d10647e1803 href="http://www.ncbi.nlm.nih.gov/pubmed/24947465">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1806 href="https://doi.org/10.1124/jpet.114.213793">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734958516"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1815 class=n-a></a>Ward K, Citrome L: Brexpiprazole for the maintenance treatment of adults with schizophrenia: An evidence-based review and place in therapy. <i>Neuropsychiatr Dis Treat.</i> 2019; <b>15</b>: 247–57. <a target=xrefwindow id=d10647e1823 href="http://www.ncbi.nlm.nih.gov/pubmed/30697049">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1826 href="https://doi.org/10.2147/NDT.S169369">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1829 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6339638">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734958516">Faculty Opinions Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736364954"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1842 class=n-a></a>Cha DS, Luo X, Ahmed J, <i> et al.</i>: Brexpiprazole as an augmentation agent to antidepressants in treatment resistant major depressive disorder. <i>Expert Rev Neurother.</i> 2019; <b>19</b>(9): 777–83. <a target=xrefwindow id=d10647e1853 href="http://www.ncbi.nlm.nih.gov/pubmed/31389279">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1856 href="https://doi.org/10.1080/14737175.2019.1653759">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736364954">Faculty Opinions Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736893597"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1870 class=n-a></a>Grossberg GT, Kohegyi E, Mergel V, <i> et al.</i>: Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. <i>Am J Geriatr Psychiatry.</i> 2020; <b>28</b>(4): 383–400. <a target=xrefwindow id=d10647e1881 href="http://www.ncbi.nlm.nih.gov/pubmed/31708380">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1884 href="https://doi.org/10.1016/j.jagp.2019.09.009">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736893597">Faculty Opinions Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d10647e1897 class=n-a></a>Caraci F, Enna SJ, Zohar J, <i> et al.</i>: A new nomenclature for classifying psychotropic drugs. <i>Br J Clin Pharmacol.</i> 2017; <b>83</b>(8): 1614–6. <a target=xrefwindow id=d10647e1908 href="http://www.ncbi.nlm.nih.gov/pubmed/28401576">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1911 href="https://doi.org/10.1111/bcp.13302">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1915 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5510058">Free Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727235400"><span class="faculty-opinion-icon small"></span></a><a name=d10647e1924 class=n-a></a>Frankel JS, Schwartz TL: Brexpiprazole and cariprazine: Distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. <i>Ther Adv Psychopharmacol.</i> 2017; <b>7</b>(1): 29–41. <a target=xrefwindow id=d10647e1932 href="http://www.ncbi.nlm.nih.gov/pubmed/28101322">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1935 href="https://doi.org/10.1177/2045125316672136">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5228714">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727235400">Faculty Opinions Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d10647e1951 class=n-a></a>Koppel J, Acker C, Davies P, <i> et al.</i>: Psychotic Alzheimer's disease is associated with gender-specific tau phosphorylation abnormalities. <i>Neurobiol Aging.</i> 2014; <b>35</b>(9): 2021–8. <a target=xrefwindow id=d10647e1962 href="http://www.ncbi.nlm.nih.gov/pubmed/24731519">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1965 href="https://doi.org/10.1016/j.neurobiolaging.2014.03.003">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1969 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4155748">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d10647e1978 class=n-a></a>Murray PS, Kirkwood CM, Gray MC, <i> et al.</i>: Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis. <i>J Alzheimers Dis.</i> 2014; <b>39</b>(4): 759–73. <a target=xrefwindow id=d10647e1989 href="http://www.ncbi.nlm.nih.gov/pubmed/24270207">PubMed Abstract </a> | <a target=xrefwindow id=d10647e1992 href="https://doi.org/10.3233/JAD-131166">Publisher Full Text </a> | <a target=xrefwindow id=d10647e1996 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4034758">Free Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734201560"><span class="faculty-opinion-icon small"></span></a><a name=d10647e2005 class=n-a></a>Cummings J, Ballard C, Tariot P, <i> et al.</i>: Pimavanserin: Potential Treatment For Dementia-Related Psychosis. <i>J PrevAlzheimers Dis.</i> 2018; <b>5</b>(4): 253–8. <a target=xrefwindow id=d10647e2016 href="http://www.ncbi.nlm.nih.gov/pubmed/30298184">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2019 href="https://doi.org/10.14283/jpad.2018.29">Publisher Full Text </a> | <a target=xrefwindow id=d10647e2023 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6413822">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734201560">Faculty Opinions Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d10647e2037 class=n-a></a>Vanover KE, Weiner DM, Makhay M, <i> et al.</i>: Pharmacological and behavioral profile of <i>N</i>-(4-fluorophenylmethyl)-<i>N</i>-(1-methylpiperidin-4-yl)-<i>N</i>'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2<i>N</i>,3<i>N</i>)-dihydroxybutanedioate (2: 1) (ACP-103), a novel 5-hydroxytryptamine<sub>2A</sub> receptor inverse agonist. <i>J Pharmacol Exp Ther.</i> 2006; <b>317</b>(2): 910–8. <a target=xrefwindow id=d10647e2067 href="http://www.ncbi.nlm.nih.gov/pubmed/16469866">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2070 href="https://doi.org/10.1124/jpet.105.097006">Publisher Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d10647e2079 class=n-a></a>Nutt D, Stahl S, Blier P, <i> et al.</i>: Inverse agonists - What do they mean for psychiatry? <i>Eur Neuropsychopharmacol.</i> 2017; <b>27</b>(1): 87–90. <a target=xrefwindow id=d10647e2090 href="http://www.ncbi.nlm.nih.gov/pubmed/27955830">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2093 href="https://doi.org/10.1016/j.euroneuro.2016.11.013">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734037125"><span class="faculty-opinion-icon small"></span></a><a name=d10647e2102 class=n-a></a>Kales HC, Lyketsos CG, Miller EM, <i> et al.</i>: Management of behavioral and psychological symptoms in people with Alzheimer's disease: An international Delphi consensus. <i>Int Psychogeriatr.</i> 2019; <b>31</b>(1): 83–90. <a target=xrefwindow id=d10647e2113 href="http://www.ncbi.nlm.nih.gov/pubmed/30068400">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2116 href="https://doi.org/10.1017/S1041610218000534">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734037125">Faculty Opinions Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718164088"><span class="faculty-opinion-icon small"></span></a><a name=d10647e2129 class=n-a></a>Cummings J, Isaacson S, Mills R, <i> et al.</i>: Pimavanserin for patients with Parkinson's disease psychosis: A randomised, placebo-controlled phase 3 trial. <i>Lancet.</i> 2014; <b>383</b>(9916): 533–40. <a target=xrefwindow id=d10647e2140 href="http://www.ncbi.nlm.nih.gov/pubmed/24183563">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2143 href="https://doi.org/10.1016/S0140-6736(13)62106-6">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718164088">Faculty Opinions Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/732699317"><span class="faculty-opinion-icon small"></span></a><a name=d10647e2156 class=n-a></a>Ballard C, Banister C, Khan Z, <i> et al.</i>: Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer's disease psychosis: A phase 2, randomised, placebo-controlled, double-blind study. <i>Lancet Neurol.</i> 2018; <b>17</b>(3): 213–22. <a target=xrefwindow id=d10647e2167 href="http://www.ncbi.nlm.nih.gov/pubmed/29452684">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2170 href="https://doi.org/10.1016/S1474-4422(18)30039-5">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/732699317">Faculty Opinions Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734664538"><span class="faculty-opinion-icon small"></span></a><a name=d10647e2183 class=n-a></a>Ballard C, Youakim JM, Coate B, <i> et al.</i>: Pimavanserin in Alzheimer's Disease Psychosis: Efficacy in Patients with More Pronounced Psychotic Symptoms. <i>J PrevAlzheimers Dis.</i> 2019; <b>6</b>(1): 27–33. <a target=xrefwindow id=d10647e2194 href="http://www.ncbi.nlm.nih.gov/pubmed/30569083">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2197 href="https://doi.org/10.14283/jpad.2018.30">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734664538">Faculty Opinions Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d10647e2211 class=n-a></a>Ballard C, Howard R: Neuroleptic drugs in dementia: Benefits and harm. <i>Nat Rev Neurosci.</i> 2006; <b>7</b>(6): 492–500. <a target=xrefwindow id=d10647e2219 href="http://www.ncbi.nlm.nih.gov/pubmed/16715057">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2222 href="https://doi.org/10.1038/nrn1926">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a name=d10647e2231 class=n-a></a>Maher AR, Maglione M, Bagley S, <i> et al.</i>: Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: A systematic review and meta-analysis. <i>JAMA.</i> 2011; <b>306</b>(12): 1359–69. <a target=xrefwindow id=d10647e2242 href="http://www.ncbi.nlm.nih.gov/pubmed/21954480">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2245 href="https://doi.org/10.1001/jama.2011.1360">Publisher Full Text </a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d10647e2254 class=n-a></a>Maust DT, Kim HM, Seyfried LS, <i> et al.</i>: Antipsychotics, Other Psychotropics, and the Risk of Death in Patients With Dementia: Number Needed to Harm. <i>JAMA Psychiatry.</i> 2015; <b>72</b>(5): 438–45. <a target=xrefwindow id=d10647e2265 href="http://www.ncbi.nlm.nih.gov/pubmed/25786075">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2268 href="https://doi.org/10.1001/jamapsychiatry.2014.3018">Publisher Full Text </a> | <a target=xrefwindow id=d10647e2272 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4439579">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a name=d10647e2281 class=n-a></a>Webster P: Pimavanserin evaluated by the FDA. <i>Lancet.</i> 2018; <b>391</b>(10132): 1762. <a target=xrefwindow id=d10647e2289 href="http://www.ncbi.nlm.nih.gov/pubmed/29739555">PubMed Abstract </a> | <a target=xrefwindow id=d10647e2292 href="https://doi.org/10.1016/S0140-6736(18)31002-X">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 08 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-686/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-686/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Drug Sciences, University of Catania, Viale Andrea Doria 6, 95125, Catania, Italy<br/> <sup>2</sup> Oasi Research Institute - IRCCS, Via Conte Ruggero 73, 94018, Troina, Italy<br/> <sup>3</sup> ASP3 Catania, Department of Mental Health, Alzheimer Psychogeriatric Center Corso Italia 234, 95127, Catania, Italy<br/> <sup>4</sup> Department of Biomedical and Biotechnological Sciences, University of Catania, Via S. Sofia 89, 95123, Catania, Italy<br/> <p> <div class=margin-bottom> Filippo Caraci <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Mario Santagati <br/> <span>Roles: </span> Conceptualization, Resources, Writing – Original Draft Preparation </div> <div class=margin-bottom> Giuseppe Caruso <br/> <span>Roles: </span> Data Curation, Methodology, Writing – Original Draft Preparation </div> <div class=margin-bottom> Dario Cannav&ograve; <br/> <span>Roles: </span> Data Curation, Writing – Review & Editing </div> <div class=margin-bottom> Gian Marco Leggio <br/> <span>Roles: </span> Resources, Writing – Original Draft Preparation </div> <div class=margin-bottom> Salvatore Salomone <br/> <span>Roles: </span> Data Curation, Writing – Review & Editing </div> <div class=margin-bottom> Filippo Drago <br/> <span>Roles: </span> Supervision, Writing – Original Draft Preparation </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-686/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 08 Jul 2020, 9:686 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22662.1">https://doi.org/10.12688/f1000research.22662.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Caraci F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=25019 data-id=22662 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22662.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-686/v1/pdf?article_uuid=0eb7289e-aacb-40eb-910c-acd2cc85c13c" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22662.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Caraci F, Santagati M, Caruso G <em>et al.</em> New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer’s disease: focus on brexpiprazole and pimavanserin [version 1; peer review: 2 approved] <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):686 (<a href="https://doi.org/10.12688/f1000research.22662.1" target=_blank>https://doi.org/10.12688/f1000research.22662.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22662 id=mobile-track-article-signin-22662 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22662?target=/articles/9-686/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=25019 /> <input name=articleId type=hidden value=22662 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Fabio Sambataro</strong>, Department of Neuroscience, University of Padova, Italy </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Dag Aarsland</strong>, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, UK </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 08 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-686/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-686/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=71379-66691></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=71380-66692></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=2><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-686/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>08 Jul 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Fabio Sambataro</strong>, Department of Neuroscience, University of Padova, Italy </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Dag Aarsland</strong>, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London, UK </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-686/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-686/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "New antipsychotic drugs for the treatment...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-686/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-686/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-686/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Caraci F et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-686/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-686",
            templates : {
                twitter : "New antipsychotic drugs for the treatment of agitation and psychosis.... Caraci F et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-686/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer\u2019s disease: focus on brexpiprazole and pimavanserin", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer\u2019s disease: focus on brexpiprazole and pimavanserin", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22662/25019")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "25019");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "66691": 1,
                           "66692": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "82d58485-e1d1-400c-857f-20b2dbae9bc3";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-686.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-686.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-686.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-686.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-686.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>